Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SJP-0130 Phase I ascending dose study in healthy Japanese adult male subjects
jRCT2051200086Phase 1Completed
- Sponsor
- Senju Pharmaceutical Co., Ltd.
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Glaucoma comparing SJP-0130 with Placebo (2 arms). Primary endpoints: Safety and tolerability and Pharmacokinetics. Started Nov 2020; status: completed.
02
Drugs
netarsudil
03
Conditions
Glaucoma
Beyond the preview
Go deeper on jRCT2051200086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200086.